Victoza for weight loss: what one week of liraglutide actually tells you

What did @rhondagsigler actually say?

Honestly? Almost nothing about Victoza. The transcript for this video is entirely song lyrics, not health commentary. There are no medical claims to evaluate here. The caption tells us she is one week into taking Victoza (liraglutide) for weight loss and felt embarrassed enough about it to almost not document the journey. That context is real and worth discussing. But the video itself appears to be background audio over presumably visual content, and the words captured are from a pop song, not a treatment diary.

So this fact-check will focus on what the caption implies: that Victoza is a reasonable tool for weight loss, and that using it carries some social stigma worth working through. Both of those things are worth examining on their own merits.

Does the science back up using Victoza for weight loss?

Partially, yes. Liraglutide has real clinical evidence behind it for weight management, but it is the weaker sibling in the GLP-1 family at this point. The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, New England Journal of Medicine) showed that 3 mg daily liraglutide produced roughly 8 percent body weight reduction over 56 weeks in non-diabetic adults with obesity. That is meaningful, but it trails behind semaglutide's roughly 15 percent in the STEP trials and tirzepatide's roughly 20 percent in SURMOUNT-1.

Victoza is FDA-approved for type 2 diabetes, not weight loss. Saxenda, the 3 mg formulation of the same molecule, is the FDA-approved weight loss version. If she is using Victoza off-label at a weight loss dose, that is a legitimate clinical practice but worth knowing. The distinction is not trivial from a coverage and dosing standpoint.

• Pi-Sunyer et al., 2015, NEJM: 8% average weight loss with liraglutide 3 mg over 56 weeks
• Wilding et al., 2021, NEJM: 15% average weight loss with semaglutide 2.4 mg (Wegovy)
• Jastreboff et al., 2022, NEJM: ~20% average weight loss with tirzepatide (Zepbound)

What did they get wrong, or right?

Credit where it is due: the caption is honest about ambivalence. Saying she debated sharing because it is controversial and she felt embarrassed is one of the more grounded things someone can say about starting a GLP-1 for weight loss on social media. Weight loss medication stigma is documented and real (Puhl and Heuer, 2010, Obesity Reviews), and normalizing treatment-seeking without overselling the drug is a reasonable public health contribution.

What she did not get wrong, because she did not say anything medical, is harder to flag. The implicit claim in the caption is that Victoza works for weight loss. That claim is mostly accurate, with the caveats above. One week of data tells you almost nothing about efficacy. Early weeks on liraglutide are typically low-dose titration weeks where appetite suppression is modest and GI side effects are common. Anyone watching expecting dramatic week-one results is going to be misinformed by the framing, even unintentionally.

What should you actually know?

Liraglutide works, but it is no longer the best GLP-1 option for most people pursuing weight loss specifically. If cost and insurance coverage allow, semaglutide (Wegovy) or tirzepatide (Zepbound) show stronger outcomes in head-to-head trial data. That said, Victoza has a long safety record, having been on the market since 2010, and some patients tolerate it better than newer agents.

Stopping liraglutide typically leads to weight regain. The SCALE Maintenance extension data and real-world follow-up studies consistently show that most weight lost returns within a year of discontinuation. This is not a character flaw. It reflects that obesity is a chronic condition with biological drivers, not a temporary problem with a fixed course of treatment. Anyone framing a one-week start as a journey to document should be prepared for that reality upfront.

• GI side effects (nausea, vomiting, diarrhea) are most common in weeks one through four during dose titration
• Thyroid C-cell tumor risk observed in rodents has not been confirmed in humans, but liraglutide carries a black box warning for patients with a personal or family history of medullary thyroid carcinoma
• Victoza is dosed at up to 1.8 mg for diabetes; Saxenda goes to 3 mg for weight management. These are not interchangeable prescriptions